Emerging escherichia coli O25b/ST131 clone predicts treatment failure in urinary tract infections

Clinical Infectious Diseases

Volumn 60, Issue 4, 2015, Pages 523-527

  Can, Fusun ^a   Kurt Azap, Ozlem ^b   Seref, Ceren ^a   Ispir, Pelin ^a   Arslan, Hande ^b   Ergonul, Onder ^a  

^a KOÇ UNIVERSITY   (Turkey)

^b BASKENT UNIVERSITY   (Turkey)

Author keywords

E. coli; ST131; treatment failure; urinary

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZTREONAM; CARBAPENEM DERIVATIVE; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; COTRIMOXAZOLE; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; GENTAMICIN; IMIPENEM; MEROPENEM; NITROFURANTOIN; NORFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE; SULTAMICILLIN; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; BACTERIUM DETECTION; BACTERIUM ISOLATION; CLONE; COHORT ANALYSIS; COLONY FORMING UNIT; CONVALESCENCE; CYSTITIS; DIABETES MELLITUS; DRUG TREATMENT FAILURE; ESCHERICHIA COLI; ESCHERICHIA COLI O25B; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; MULTIPLEX POLYMERASE CHAIN REACTION; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION; URINALYSIS; URINARY TRACT INFECTION; URINE CULTURE; AGED; BACTERIUM IDENTIFICATION; CLASSIFICATION; DRUG EFFECTS; ESCHERICHIA COLI INFECTIONS; FORECASTING; GENETICS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHYLOGENY; TREATMENT FAILURE; TURKEY; URINARY TRACT INFECTIONS;

AGED; ANTI-BACTERIAL AGENTS; BACTERIAL TYPING TECHNIQUES; CEFUROXIME; CIPROFLOXACIN; COHORT STUDIES; CYSTITIS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; FORECASTING; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; MULTIVARIATE ANALYSIS; PHYLOGENY; PROSPECTIVE STUDIES; TREATMENT FAILURE; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; TURKEY; URINARY TRACT INFECTIONS;

EID: 84922386744     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu864     Document Type: Article

References (23)

1. Barber AE, Norton JP, Spivak AM, Mulvey MA. Urinary tract infections: current and emerging management strategies. Clin Infect Dis 2013; 57:719-24
2. Coque TM, Baquero F, Canton R. Increasing prevalence of ESBLproducing Enterobacteriaceae in Europe. Euro Surveill 2008; 13: pii:19044
3. Lopez-Cerero L, Navarro MD, Bellido M, et al. Escherichia coli belonging to the worldwide emerging epidemic clonal group O25b/ST131: risk factors and clinical implications. J Antimicrob Chemother 2014; 69:809-14
4. Johnson JR, Johnston B, Clabots C, Kuskowski MA, Castanheira M. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin Infect Dis 2010; 51:286-94
5. Rogers BA, Sidjabat HE, Paterson DL. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-Associated strain. J Antimicrob Chemother 2011; 66:1-14
6. Lau SH, Reddy S, Cheesbrough J, et al. Major uropathogenic Escherichia coli strain isolated in the northwest of England identified by multilocus sequence typing. J Clin Microbiol 2008; 46:1076-80
7. Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V, et al. Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. J Antimicrob Chemother 2008; 61:273-81
8. Banerjee R, Robicsek A, Kuskowski MA, et al. Molecular epidemiology of Escherichia coli sequence type 131 and Its H30 and H30-Rx subclones among extended-spectrum-beta-lactamase-positive and -negative E. coli clinical isolates from the Chicago region, 2007 to 2010. Antimicrob Agents Chemother 2013; 57:6385-8
9. Clinical and Laboratory Standards Institute . Performance standards for Antimicrobial Susceptibility Testing: 20th Informational Supplement. Wayne, PA: CLSI, 2010
10. Adams-Sapper S, Diep BA, Perdreau-Remington F, Riley LW. Clonal composition and community clustering of drug-susceptible and -resistant Escherichia coli isolates from bloodstream infections. Antimicrob Agents Chemother 2013; 57:490-7
11. Clermont O, Bonacorsi S, Bingen E. Rapid and simple determination of the Escherichia coli phylogenetic group. Appl Environ Microbiol 2000; 66:4555-8
12. Wang H, Liddell CA, Coates MM, et al. Global, regional, and national levels of neonatal, infant, and under-5 mortality during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014; 384:957-79
13. ArslanH, AzapOK, Ergonul O, Timurkaynak F. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from communityacquired urinary tract infections in Turkey. J Antimicrob Chemother 2005; 56:914-8
14. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52:e103-20
15. Banerjee R, Johnston B, Lohse C, Porter SB, Clabots C, Johnson JR. Escherichia coli sequence type 131 is a dominant, antimicrobialresistant clonal group associated with healthcare and elderly hosts. Infect Control Hosp Epidemiol 2013; 34:361-9
16. Cagnacci S, Gualco L, Debbia E, Schito GC, Marchese A. European emergence of ciprofloxacin-resistant Escherichia coli clonal groups O25:H4-ST 131 and O15:K52:H1 causing community-Acquired uncomplicated cystitis. J Clin Microbiol 2008; 46:2605-12
17. Banerjee R, Johnson JR. A new clone sweeps clean: the enigmatic emergence of Escherichia coli ST131. Antimicrob Agents Chemother 2014; 58:4997-5004
18. Novais A, Sousa C, de Dios Caballero J, et al. MALDI-TOF mass spectrometry as a tool for the discrimination of high-risk Escherichia coli clones from phylogenetic groups B2 (ST131) and D (ST69, ST405, ST393). Eur J Clin Microbiol Infect Dis 2014; 33:1391-9
19. Matsumura Y, Yamamoto M, Nagao M, et al. Detection of extendedspectrum-beta-lactamase-producing Escherichia coli ST131 and ST405 clonal groups by matrix-Assisted laser desorption ionizationtime of flight mass spectrometry. J Clin Microbiol 2014; 52: 1034-40
20. Johnson JR, Urban C, Weissman SJ, et al. Molecular epidemiological analysis of Escherichia coli sequence type ST131 (O25:H4) and blaCTXM-15 among extended-spectrum-beta-lactamase-producing E. coli from the United States, 2000 to 2009. Antimicrob Agents Chemother 2012; 56:2364-70
21. Johnson JR, Tchesnokova V, Johnston B, et al. Abrupt emergence of a single dominant multidrug-resistant strain of Escherichia coli. J Infect Dis 2013; 207:919-28
22. Johnson JR, Menard M, Johnston B, Kuskowski MA, Nichol K, Zhanel GG. Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002 to 2004. Antimicrob Agents Chemother 2009; 53:2733-9
23. Colpan A, Johnston B, Porter S, et al. Escherichia coli sequence type 131 (ST131) subclone H30 as an emergent multidrug-resistant pathogen among US veterans. Clin Infect Dis 2013; 57:1256-65